Who are Fate Therapeutics's decision-makers?
Fate Therapeutics's official leadership and governance pages are the safest source for named executives.
- Primary buyers
- Finance, procurement, IT, security, operations, legal, and business leadership
- Company status
- Public company; Nasdaq: FATE
- HQ
- San Diego, United States
- Category
- Cell therapy company
- Decision style
- Public-company buying committee
- Best source
- Official leadership or IR page
- Fate Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Fate Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Fate Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
Who leads Fate Therapeutics?
Fate Therapeutics's named leaders should be verified directly on the company's official leadership, governance, or investor-relations page.
Who owns buying decisions at Fate Therapeutics?
The buying committee depends on the offer and usually spans finance, procurement, legal, IT/security, and the business owner.
How should sellers map the account?
Start with headquarters and public leadership, then map functional owners by product area, job posts, filings, partner announcements, and investor materials.
As of June 2026.Sources:Fate Therapeutics official websiteFate Therapeutics investor relations or company newsBuiltWith public technology profile
Fate Therapeutics — frequently asked questions
Read the full Fate Therapeutics profile
More on Fate Therapeutics
Who are Fate Therapeutics's decision-makers — other companies
Revenue work. On autopilot.
Start Free TrialBuilt for revenue teams who care about quality.